Kyntra Bio
KYNB
Kyntra Bio (KYNB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.96
- EPS estimate
- $2.96
- EPS surprise
- +0.00%
- Revenue surprise
- −14.10%
- Revenue
- −$1.5M
- Revenue estimate
- −$1.3M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $2.96 | $2.96 | +0.00% | −$1.5M | SEC |
| Q1 2026 | May 11, 2026 | −$3.36 | −$3.76 | −12.07% | $3.7M | SEC |
| Q4 2025 | Mar 16, 2026 | −$3.89 | −$3.51 | +9.65% | $1.3M | SEC |
| Q3 2025 | Nov 10, 2025 | −$4.01 | $49.61 | +1338.08% | $1.1M | SEC |
| Q2 2025 | Aug 11, 2025 | −$2.30 | −$1.88 | +18.38% | $1.3M | SEC |
| Q1 2025 | May 12, 2025 | $0.75 | $1.25 | +66.67% | $2.7M | SEC |
| Q4 2024 | Mar 17, 2025 | −$3.50 | $4.50 | +228.57% | $3.1M | SEC |
| Q3 2024 | Nov 12, 2024 | −$7.66 | −$4.25 | +44.50% | $46.3M | SEC |
| Q2 2024 | Aug 6, 2024 | −$8.00 | −$4.00 | +50.00% | $50.6M | SEC |
| Q1 2024 | May 6, 2024 | −$10.45 | −$8.25 | +21.06% | $55.9M | SEC |
| Q4 2023 | Feb 26, 2024 | −$10.63 | −$14.25 | −34.12% | $27.1M | SEC |
| Q3 2023 | Nov 6, 2023 | −$17.03 | −$16.25 | +4.56% | $40.1M | SEC |
| Q2 2023 | Aug 7, 2023 | −$17.60 | −$22.50 | −27.86% | $44.3M | SEC |
| Q1 2023 | May 8, 2023 | −$18.83 | −$20.25 | −7.52% | $36.2M | SEC |
| Q4 2022 | Feb 27, 2023 | −$23.46 | −$17.50 | +25.40% | $34.4M | SEC |
| Q3 2022 | Nov 7, 2022 | −$20.25 | −$24.50 | −20.99% | $15.7M | SEC |
| Q2 2022 | Aug 8, 2022 | −$23.04 | −$19.50 | +15.37% | $29.8M | SEC |
| Q1 2022 | May 9, 2022 | −$20.79 | −$17.00 | +18.24% | $60.8M | SEC |
| Q4 2021 | Feb 28, 2022 | −$16.57 | −$36.25 | −118.75% | $16.5M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.18 | $13.50 | +7814.29% | $156.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Kyntra Bio (KYNB) last report earnings?
Kyntra Bio last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did KYNB beat earnings estimates?
Kyntra Bio reported EPS of $2.96 for Q2 2026, in line with the $2.96 consensus estimate.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.